Natural killer cells: a promising immunotherapy for cancer

J Chu, F Gao, M Yan, S Zhao, Z Yan, B Shi… - Journal of translational …, 2022 - Springer
As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have
recently gained attention as an important type of innate immune regulatory cell. NK cells can …

Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance

A Ashrafi, Z Akter, P Modareszadeh, P Modareszadeh… - Cancers, 2022 - mdpi.com
Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance

J Seo, J Ha, E Kang, S Cho - Archives of pharmacal research, 2021 - Springer
The complex orchestration of gene expression that mediates the transition of epithelial cells
into mesenchymal cells is implicated in cancer development and metastasis. As the primary …

[HTML][HTML] Mechanisms of action and clinical implications of MicroRNAs in the drug resistance of gastric cancer

Y Liu, X Ao, G Ji, Y Zhang, W Yu, J Wang - Frontiers in oncology, 2021 - frontiersin.org
Gastric cancer (GC) is one of the most common malignant tumors of digestive systems
worldwide, with high recurrence and mortality. Chemotherapy is still the standard treatment …

Current opinion on the pharmacogenomics of paclitaxel-induced toxicity

ZN Al-Mahayri, MM AlAhmad, BR Ali - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction: Paclitaxel is a microtubule stabilizer that is currently one of the most utilized
chemotherapeutic agents. Its efficacy in breast, uterine, lung and other neoplasms made its …

[HTML][HTML] MicroRNAs as predictors of lung-cancer resistance and sensitivity to cisplatin

M Konoshenko, Y Lansukhay, S Krasilnikov… - International journal of …, 2022 - mdpi.com
Background: Platinum-based chemotherapy, cisplatin (DDP) specifically, is the main
strategy for treating lung cancer (LC). However, currently, there is a lack of predictive drug …

An antioxidant feedforward cycle coordinated by linker histone variant H1. 2 and NRF2 that drives nonsmall cell lung cancer progression

Y Chen, J Shi, X Wang, L Zhou… - Proceedings of the …, 2023 - National Acad Sciences
Nonsmall cell lung cancer (NSCLC) is highly malignant with limited treatment options,
platinum-based chemotherapy is a standard treatment for NSCLC with resistance commonly …

Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells

J Park, GE Lee, HJ An, CJ Lee, ES Cho… - Archives of Pharmacal …, 2021 - Springer
Resolution to chemoresistance is a major challenge in patients with advanced-stage
malignancies. Thus, identification of action points and elucidation of molecular mechanisms …

Nanomedicine-based adjuvant therapy: a promising solution for lung cancer

Y Xu, JC Hsu, L Xu, W Chen, W Cai, K Wang - Journal of …, 2023 - Springer
Lung cancer has been the leading cause of cancer-related deaths worldwide for decades.
Despite the increasing understanding of the underlying disease mechanisms, the prognosis …

Cancer bioenergetics and tumor microenvironments—Enhancing chemotherapeutics and targeting resistant niches through nanosystems

A Farhana, A Alsrhani, YS Khan, Z Rasheed - Cancers, 2023 - mdpi.com
Simple Summary Cancer remains a major killer of the human population. Current cancer
diagnostic and therapeutic methods are associated with shortcomings of limited targetability …